NGS

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

Retrieved on: 
Thursday, February 15, 2024

LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023.

Key Points: 
  • LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023.
  • The Company plans to issue another announcement following today’s report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events.
  • Total billable volume of 734 tests during the second quarter (representing 69% of all tests in the period, including non-billable study tests).
  • Operating cost reductions commenced during the fiscal second quarter continued with a fiscal third quarter cash burn target approximately 33% less than in the prior quarter and approximately 50% less than in the first quarter of fiscal 2024.

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.

Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test.
  • The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies.
  • This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing.

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Retrieved on: 
Monday, February 12, 2024

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

Retrieved on: 
Monday, February 12, 2024

PARSIPPANY, N.J., Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

Volta Labs Partners with OEM by QIAGEN to Unlock Potential of NGS Sample Prep

Retrieved on: 
Thursday, February 8, 2024

Volta Labs and OEM by QIAGEN will partner on the production of reagents and other elements necessary for the development of the Callisto sample preparation kits.

Key Points: 
  • Volta Labs and OEM by QIAGEN will partner on the production of reagents and other elements necessary for the development of the Callisto sample preparation kits.
  • "QIAGEN has paved the way for the acceleration of sample prep and has set the standard for many genomics workflows," said Udayan Umapathi, CEO at Volta Labs.
  • "At OEM by QIAGEN, we are committed to supporting companies like Volta Labs in their mission to revolutionize the field of molecular biology.
  • In supplying reagents for their innovative Callisto Sample Prep System, our partnership aims to elevate NGS technology, addressing the critical bottleneck in NGS sample & library preparation," said Salim Essakali, VP, Head of the OEM Business at QIAGEN.

Sysmex and Hitachi High-Tech Agree to Collaborate on Development of New Genetic Testing Systems

Retrieved on: 
Thursday, February 8, 2024

TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).

Key Points: 
  • TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).
  • To achieve widespread clinical realization, Sysmex and Hitachi High-Tech will develop more efficient genetic testing systems at a lower cost, aiming at expanding optimal genetic testing for individual diseases.
  • In recent years, there has been active development of assay reagents using next generation sequencer (NGS)(2) in the genetic testing field.
  • Having achieved the milestones in the FS agreement, Sysmex and Hitachi High-Tech have agreed, as the next step, to collaborate on the development of genetic testing systems with a view to their widespread adoption in the clinical setting.

Fapon at Medlab Middle East 2024: Advancing Local Healthcare through IVD Technologies

Retrieved on: 
Wednesday, February 7, 2024

Dedicated to leveraging its cutting-edge technologies and vast industry experience, Fapon aims to support the growth of the local IVD industry, enhancing local healthcare services while strengthening its global diagnostics ecosystem.

Key Points: 
  • Dedicated to leveraging its cutting-edge technologies and vast industry experience, Fapon aims to support the growth of the local IVD industry, enhancing local healthcare services while strengthening its global diagnostics ecosystem.
  • Committed to empowering local IVD companies and boosting the development of the local healthcare industry in the Middle East, Fapon has established a strategic partnership with the China Innovation Center (C.I.C.)
  • This collaboration aims to introduce Fapon's innovative technologies, products, and services in diagnostics and therapeutics for the medical advancement of the local healthcare industry.
  • Looking ahead, Fapon will remain rooted in the local market in the Middle East, strengthening collaborations with local partners and enhancing healthcare services for the local region.

Complete Genomics and seqWell Announce Codevelopment Partnership at AGBT

Retrieved on: 
Wednesday, February 7, 2024

SAN JOSE, Calif. and BEVERLY, Mass., Feb. 7, 2024 /PRNewswire/ -- Complete Genomics, a life sciences company specializing in end-to-end DNA sequencing solutions, and seqWell, a global provider of genomic library preparation workflow solutions, today announced a partnership aimed at expanding the range of library preparation product offerings available to Complete Genomics customers. The companies will work together to ensure seqWell-developed products are compatible with the entire Complete Genomics next-generation sequencing (NGS) and automation portfolios.

Key Points: 
  • The companies will work together to ensure seqWell-developed products are compatible with the entire Complete Genomics next-generation sequencing (NGS) and automation portfolios.
  • "Our partnership with seqWell enables us to offer a broader range of tools to support a broader range of customer needs."
  • Leveraging the power of the Complete Genomics DNBSEQ-G400RS * and seqWell purePlex ™ DNA Library Prep Kit , this partnership will allow customers to the ability to run cost-effective and scalable workflows pairing seqWell library prep kits with Complete Genomics' portfolio of DNBSEQ technologies.
  • The latest outcome of this partnership enables customers to pair seqWell's ExpressPlex ™ library prep kits with Complete Genomics' portfolio of DNBSEQ technologies, including the DNBSEQ-G-99 RS* and DNBSEQ-T7 RS* sequencers.

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

Retrieved on: 
Wednesday, February 7, 2024

BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country.

Key Points: 
  • The program from SOPHiA GENETICS and AstraZeneca Spain started in 2022, when AstraZeneca and SOPHiA GENETICS collaborated to deploy HRD testing to five labs throughout the country.
  • With today's announcement, AstraZeneca Spain named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain.
  • Together, SOPHiA GENETICS and AstraZeneca are offering the option for HRD testing to become available to even more laboratories throughout the country to help facilitate in-house HRD detection.
  • Hence our agreement with SOPHiA GENETICS, to offer hospital centers throughout Spain the possibility of making an accurate diagnosis for patients with ovarian cancer."